Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
2D and 3D models
Eribulin
Invasion
Migration
Proliferation
Sarcoma
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
04 Dec 2021
04 Dec 2021
Historique:
received:
26
07
2021
accepted:
12
11
2021
entrez:
5
12
2021
pubmed:
6
12
2021
medline:
6
12
2021
Statut:
epublish
Résumé
Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been approved for advanced liposarcoma (LPS). In this study, we evaluated the effect of eribulin on proliferation, migration and invasion capabilities in LPS, leiomyosarcoma (LMS) and fibrosarcoma (FS) models, using both monolayer (2D) and three-dimensional (3D) spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the treatment of STS with the aim of increasing its antitumour activity. Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line models. Furthermore, we provide data that suggest, for the first time, a synergistic effect with ifosfamide in all models, and with pazopanib in LMS as well as in myxoid and pleomorphic LPS. Our results support the effect of eribulin on LPS, LMS and FS cell line models. The combination of eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.
Sections du résumé
BACKGROUND
BACKGROUND
Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been approved for advanced liposarcoma (LPS).
METHODS
METHODS
In this study, we evaluated the effect of eribulin on proliferation, migration and invasion capabilities in LPS, leiomyosarcoma (LMS) and fibrosarcoma (FS) models, using both monolayer (2D) and three-dimensional (3D) spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the treatment of STS with the aim of increasing its antitumour activity.
RESULTS
RESULTS
Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line models. Furthermore, we provide data that suggest, for the first time, a synergistic effect with ifosfamide in all models, and with pazopanib in LMS as well as in myxoid and pleomorphic LPS.
CONCLUSIONS
CONCLUSIONS
Our results support the effect of eribulin on LPS, LMS and FS cell line models. The combination of eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.
Identifiants
pubmed: 34863177
doi: 10.1186/s12935-021-02337-5
pii: 10.1186/s12935-021-02337-5
pmc: PMC8642967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
646Informations de copyright
© 2021. The Author(s).
Références
J Exp Clin Cancer Res. 2019 Feb 6;38(1):56
pubmed: 30728057
Cancers (Basel). 2020 Aug 21;12(9):
pubmed: 32825725
Anal Cell Pathol (Amst). 2018 Jun 21;2018:8987568
pubmed: 30034996
Semin Diagn Pathol. 2019 Mar;36(2):122-128
pubmed: 30852046
Bioinformatics. 2017 Aug 1;33(15):2413-2415
pubmed: 28379339
Hematol Oncol Clin North Am. 2013 Oct;27(5):957-74
pubmed: 24093170
Bio Protoc. 2016 Nov 5;6(21):
pubmed: 28573164
Curr Med Chem. 2020;27(29):4778-4788
pubmed: 31830880
Anticancer Res. 2012 May;32(5):1611-9
pubmed: 22593439
JAMA Oncol. 2016 Jul 1;2(7):937-40
pubmed: 27124835
Int J Mol Sci. 2018 Feb 21;19(2):
pubmed: 29466296
Am J Surg Pathol. 2021 Jan;45(1):e1-e23
pubmed: 32796172
Molecules. 2016 Dec 03;21(12):
pubmed: 27918490
Signal Transduct Target Ther. 2020 Sep 23;5(1):195
pubmed: 32963243
Anticancer Res. 2019 Aug;39(8):4031-4041
pubmed: 31366485
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
Biochemistry. 2010 Feb 16;49(6):1331-7
pubmed: 20030375
Mar Drugs. 2015 Aug 07;13(8):5016-58
pubmed: 26262627
Adv Drug Deliv Rev. 2014 Dec 15;79-80:155-71
pubmed: 25109853
Anticancer Res. 2016 Nov;36(11):6077-6082
pubmed: 27793935
Br J Cancer. 2021 Apr;124(9):1581-1591
pubmed: 33723394
Br J Cancer. 2014 Mar 18;110(6):1497-505
pubmed: 24569463
Nucleic Acids Res. 2021 Jul 2;49(W1):W174-W184
pubmed: 34060634
J Clin Oncol. 2018 Jan 10;36(2):144-150
pubmed: 29220301
Int J Cancer. 2006 Dec 15;119(12):2922-30
pubmed: 17013893
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Sci Rep. 2019 Apr 8;9(1):5759
pubmed: 30962488
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13
pubmed: 26949479
Nat Rev Drug Discov. 2010 Oct;9(10):790-803
pubmed: 20885410
Pediatr Blood Cancer. 2013 Aug;60(8):1325-32
pubmed: 23553917
Semin Diagn Pathol. 2019 Mar;36(2):112-121
pubmed: 30852045
Lab Invest. 2013 Oct;93(10):1100-14
pubmed: 23958880
Oncotarget. 2016 Dec 27;7(52):86594-86607
pubmed: 27863409
Methods Mol Biol. 2018;1711:351-398
pubmed: 29344898
Jpn J Clin Oncol. 2018 Jun 1;48(6):503-513
pubmed: 29684209
Oncotarget. 2019 Jan 4;10(2):161-174
pubmed: 30719211
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Lancet Oncol. 2011 Oct;12(11):1045-52
pubmed: 21937277
Lancet. 2016 Apr 16;387(10028):1629-37
pubmed: 26874885
Front Pharmacol. 2015 Sep 01;6:181
pubmed: 26388771
Cancer Sci. 2014 Oct;105(10):1334-42
pubmed: 25060424
Anticancer Res. 2016 Apr;36(4):1553-61
pubmed: 27069131
PLoS Comput Biol. 2019 May 20;15(5):e1006752
pubmed: 31107860
Cancer Med. 2019 Feb;8(2):585-592
pubmed: 30632291
Front Oncol. 2018 Nov 02;8:500
pubmed: 30456204